Genomic Health Inc. (NASDAQ:GHDX) insider James J. Vaughn sold 3,000 shares of the business’s stock in a transaction on Thursday, October 6th. The stock was sold at an average price of $29.68, for a total transaction of $89,040.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
James J. Vaughn also recently made the following trade(s):
- On Monday, August 8th, James J. Vaughn sold 3,000 shares of Genomic Health stock. The stock was sold at an average price of $28.74, for a total transaction of $86,220.00.
Genomic Health Inc. (NASDAQ:GHDX) opened at 29.30 on Monday. The stock’s 50 day moving average is $28.36 and its 200 day moving average is $27.34. Genomic Health Inc. has a 52 week low of $20.05 and a 52 week high of $35.79. The company’s market capitalization is $977.04 million.
Genomic Health (NASDAQ:GHDX) last announced its quarterly earnings data on Tuesday, August 2nd. The company reported ($0.18) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.18). The firm had revenue of $81.97 million for the quarter, compared to the consensus estimate of $81.27 million. Genomic Health had a negative net margin of 8.84% and a negative return on equity of 21.02%. The company’s revenue was up 16.1% on a year-over-year basis. During the same period last year, the firm earned ($0.29) EPS. On average, equities research analysts expect that Genomic Health Inc. will post ($0.47) earnings per share for the current year.
Several analysts have weighed in on the stock. Zacks Investment Research downgraded shares of Genomic Health from a “hold” rating to a “sell” rating in a research note on Thursday, August 4th. Canaccord Genuity reissued a “buy” rating and issued a $38.00 price target on shares of Genomic Health in a research note on Friday, August 5th. Leerink Swann reissued a “buy” rating on shares of Genomic Health in a research note on Tuesday, June 21st. Jefferies Group boosted their price target on shares of Genomic Health from $25.00 to $27.00 and gave the stock a “hold” rating in a research note on Wednesday, August 17th. Finally, Bank of America Corp. set a $28.00 price target on shares of Genomic Health and gave the stock a “sell” rating in a research note on Wednesday, August 3rd. Two analysts have rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $32.50.
Several hedge funds have recently made changes to their positions in the stock. HBK Investments L P purchased a new stake in shares of Genomic Health during the first quarter valued at approximately $886,000. California State Teachers Retirement System increased its stake in shares of Genomic Health by 4.0% in the second quarter. California State Teachers Retirement System now owns 39,167 shares of the company’s stock valued at $1,014,000 after buying an additional 1,510 shares during the last quarter. Kimelman & Baird LLC increased its stake in shares of Genomic Health by 2.3% in the first quarter. Kimelman & Baird LLC now owns 21,940 shares of the company’s stock valued at $543,000 after buying an additional 500 shares during the last quarter. Loomis Sayles & Co. L P purchased a new stake in shares of Genomic Health during the first quarter valued at approximately $15,639,000. Finally, Royce & Associates LP increased its stake in shares of Genomic Health by 15.7% in the second quarter. Royce & Associates LP now owns 88,500 shares of the company’s stock valued at $2,292,000 after buying an additional 12,000 shares during the last quarter. Hedge funds and other institutional investors own 88.92% of the company’s stock.
About Genomic Health
Genomic Health, Inc is a healthcare company, which provides genomic-based diagnostic tests for the treatment of early stage cancer. The Company offers its Oncotype DX tests as a clinical laboratory service, where it analyzes the expression levels of genes in tumor tissue samples and provides physicians with a quantitative gene expression profile expressed as a single quantitative score, which it calls a Recurrence Score for invasive breast cancer and colon cancer, a DCIS Score for ductal carcinoma in situ (DCIS) and a Genomic Prostate Score for prostate cancer.
Receive News & Ratings for Genomic Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.